lacosamide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4310	175481-36-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ertosamide SPM-927 lacosamide erlosamide harkoseride vimpat	a functionalized amino acid, selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing, indicated for partial-onset seizures Molecular weight: 250.30 Formula: C13H18N2O3 CLOGP: 0.39 LIPINSKI: 0 HAC: 5 HDO: 2 TPSA: 67.43 ALOGS: -2.73 ROTB: 6 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ertosamide
SPM-927
lacosamide
erlosamide
harkoseride
vimpat

a functionalized amino acid, selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing, indicated for partial-onset seizures

Molecular weight: 250.30
Formula: C13H18N2O3
CLOGP: 0.39
LIPINSKI: 0
HAC: 5
HDO: 2
TPSA: 67.43
ALOGS: -2.73
ROTB: 6

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.30	g	O
0.30	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	2 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	40 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	22.83 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	0.58 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.57 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.85 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	12.30 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Aug. 29, 2008	EMA
Oct. 28, 2008	FDA	UCB INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Seizure	2043.84	44.42	510	2148	23956	2331471
Status epilepticus	1014.40	44.42	193	2465	2285	2353142
Off label use	690.95	44.42	295	2363	73303	2282124
Generalised tonic-clonic seizure	592.00	44.42	142	2516	5230	2350197
Epilepsy	591.44	44.42	138	2520	4501	2350926
Overdose	423.72	44.42	146	2512	19761	2335666
Drug ineffective	419.07	44.42	233	2425	101391	2254036
Pregnancy	355.81	44.42	103	2555	7846	2347581
Partial seizures	232.17	44.42	48	2610	864	2354563
Dizziness	208.65	44.42	123	2535	58542	2296885
Diplopia	191.29	44.42	53	2605	3412	2352015
Somnolence	178.00	44.42	82	2576	23403	2332024
Focal dyscognitive seizures	175.64	44.42	35	2623	518	2354909
Maternal exposure during pregnancy	165.12	44.42	68	2590	14795	2340632
Multiple-drug resistance	164.10	44.42	29	2629	212	2355215
Bradycardia	154.20	44.42	58	2600	9923	2345504
Abortion spontaneous	134.11	44.42	57	2601	13388	2342039
Petit mal epilepsy	131.92	44.42	29	2629	704	2354723
Tremor	131.42	44.42	64	2594	20597	2334830
Cardiac arrest	128.36	44.42	57	2601	14873	2340554
Drug reaction with eosinophilia and systemic symptoms	126.53	44.42	43	2615	5475	2349952
Depression	123.75	44.42	68	2590	28064	2327363
Irritability	120.11	44.42	43	2615	6384	2349043
Premature delivery	114.61	44.42	35	2623	3165	2352262
Myoclonus	109.95	44.42	32	2626	2451	2352976
Exposure during pregnancy	102.75	44.42	58	2600	25161	2330266
Balance disorder	102.71	44.42	43	2615	9704	2345723
Change in seizure presentation	101.88	44.42	15	2643	25	2355402
Completed suicide	101.20	44.42	54	2604	20980	2334447
Fall	98.41	44.42	71	2587	47028	2308399
Psychotic disorder	97.66	44.42	34	2624	4645	2350782
Vomiting	95.89	44.42	83	2575	71519	2283908
Tachycardia	95.82	44.42	48	2610	16361	2339066
Coma	92.22	44.42	39	2619	9017	2346410
Aura	90.75	44.42	18	2640	259	2355168
Intentional overdose	90.14	44.42	41	2617	11280	2344147
Electrocardiogram QRS complex prolonged	89.97	44.42	23	2635	1079	2354348
Respiratory acidosis	86.38	44.42	21	2637	800	2354627
Confusional state	85.87	44.42	51	2607	24293	2331134
Anxiety	84.46	44.42	54	2604	29305	2326122
Aphasia	80.96	44.42	30	2628	4898	2350529
Mitochondrial DNULL mutation	80.70	44.42	11	2647	6	2355421
Atrioventricular block complete	79.65	44.42	22	2636	1392	2354035
Encephalopathy	79.49	44.42	29	2629	4532	2350895
Laryngeal stenosis	77.26	44.42	13	2645	68	2355359
Abnormal behaviour	74.62	44.42	28	2630	4732	2350695
Gait disturbance	73.71	44.42	45	2613	22500	2332927
Atrioventricular block	73.48	44.42	20	2638	1197	2354230
Sudden unexplained death in epilepsy	73.41	44.42	13	2645	96	2355331
Disturbance in attention	73.27	44.42	29	2629	5656	2349771
Memory impairment	73.04	44.42	37	2621	12886	2342541
Propofol infusion syndrome	72.83	44.42	13	2645	101	2355326
Drug interaction	72.55	44.42	49	2609	29114	2326313
Vertigo	71.58	44.42	33	2625	9351	2346076
Fatigue	71.04	44.42	76	2582	84797	2270630
Loss of consciousness	70.56	44.42	41	2617	18726	2336701
Dysarthria	70.38	44.42	29	2629	6273	2349154
Amnesia	69.73	44.42	30	2628	7223	2348204
Rash	69.57	44.42	64	2594	59494	2295933
Weight increased	66.46	44.42	42	2616	22295	2333132
Electrocardiogram PR prolongation	63.63	44.42	12	2646	130	2355297
Drug ineffective for unapproved indication	63.59	44.42	22	2636	2944	2352483
Toxicity to various agents	62.89	44.42	47	2611	32707	2322720
Headache	60.44	44.42	68	2590	80111	2275316
Gamma-glutamyltransferase increased	60.09	44.42	25	2633	5537	2349890
Suicide attempt	59.96	44.42	31	2627	11251	2344176
Partial seizures with secondary generalisation	56.56	44.42	10	2648	73	2355354
Metabolic acidosis	54.99	44.42	24	2634	5974	2349453
Drug resistance	54.46	44.42	19	2639	2605	2352822
Abortion induced	53.07	44.42	20	2638	3416	2352011
Condition aggravated	52.87	44.42	42	2616	31937	2323490
Ataxia	51.55	44.42	18	2640	2474	2352953
Simple partial seizures	51.13	44.42	10	2648	133	2355294
Cognitive disorder	50.86	44.42	22	2636	5359	2350068
Caesarean section	49.73	44.42	20	2638	4061	2351366
Intentional self-injury	49.51	44.42	20	2638	4107	2351320
Gene mutation	48.73	44.42	10	2648	172	2355255
Stillbirth	48.33	44.42	15	2643	1426	2354001
Ventricular tachycardia	48.22	44.42	18	2640	2993	2352434
Lipids abnormal	48.11	44.42	9	2649	93	2355334
Seizure cluster	47.84	44.42	8	2650	40	2355387
Electroencephalogram abnormal	47.17	44.42	13	2645	814	2354613
Hyponatraemia	47.12	44.42	28	2630	13297	2342130
Nausea	46.68	44.42	71	2587	112118	2243309
Head injury	46.51	44.42	19	2639	4015	2351412
Suicidal ideation	46.40	44.42	26	2632	11061	2344366
Myoclonic epilepsy	46.05	44.42	10	2648	228	2355199
Ventricular fibrillation	45.91	44.42	16	2642	2185	2353242
Arrhythmia	45.32	44.42	21	2637	6007	2349420
Atrioventricular block second degree	44.97	44.42	12	2646	665	2354762
Death	44.87	44.42	59	2599	81409	2274018

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Seizure	1751.05	38.75	463	1751	19978	1724589
Status epilepticus	649.09	38.75	136	2078	1910	1742657
Off label use	586.13	38.75	239	1975	38332	1706235
Generalised tonic-clonic seizure	516.06	38.75	128	2086	3918	1740649
Epilepsy	385.00	38.75	101	2113	3858	1740709
Drug ineffective	270.26	38.75	167	2047	63634	1680933
Overdose	238.84	38.75	100	2114	16601	1727966
Partial seizures	228.86	38.75	48	2166	663	1743904
Foetal exposure during pregnancy	154.20	38.75	56	2158	6303	1738264
Focal dyscognitive seizures	151.82	38.75	30	2184	300	1744267
Aggression	151.48	38.75	59	2155	8056	1736511
Sudden unexplained death in epilepsy	150.85	38.75	26	2188	110	1744457
Somnolence	142.65	38.75	70	2144	16669	1727898
Dizziness	136.75	38.75	87	2127	34274	1710293
Bradycardia	107.72	38.75	50	2164	10484	1734083
Fall	95.99	38.75	64	2150	27150	1717417
Toxicity to various agents	87.33	38.75	62	2152	29079	1715488
Multiple-drug resistance	83.00	38.75	18	2196	292	1744275
Atrioventricular block	82.12	38.75	24	2190	1347	1743220
Agitation	81.63	38.75	42	2172	10984	1733583
Drug resistance	80.23	38.75	29	2185	3201	1741366
Cardiac arrest	77.51	38.75	46	2168	15884	1728683
Atrioventricular block complete	76.13	38.75	23	2191	1448	1743119
Ataxia	73.26	38.75	25	2189	2328	1742239
Premature baby	71.51	38.75	26	2188	2916	1741651
Maternal exposure during pregnancy	67.91	38.75	18	2196	702	1743865
Encephalopathy	67.77	38.75	28	2186	4424	1740143
Confusional state	65.32	38.75	46	2168	21232	1723335
Atrioventricular block second degree	65.32	38.75	17	2197	617	1743950
Atrial septal defect	65.00	38.75	20	2194	1338	1743229
Petit mal epilepsy	62.26	38.75	16	2198	552	1744015
Vomiting	62.26	38.75	57	2157	38258	1706309
Aura	61.72	38.75	12	2202	109	1744458
Congenital hypoplasia of depressor angularis oris muscle	59.61	38.75	8	2206	0	1744567
Hepatocellular injury	58.40	38.75	23	2191	3208	1741359
Diplopia	56.13	38.75	21	2193	2549	1742018
Cognitive disorder	55.14	38.75	24	2190	4306	1740261
Gait disturbance	54.91	38.75	34	2180	12636	1731931
Suicide attempt	54.23	38.75	28	2186	7353	1737214
Balance disorder	51.38	38.75	25	2189	5787	1738780
Acoustic stimulation tests abnormal	49.31	38.75	8	2206	21	1744546
Syncope	49.01	38.75	33	2181	14136	1730431
Cholestasis	48.91	38.75	21	2193	3644	1740923
Partial seizures with secondary generalisation	48.88	38.75	9	2205	59	1744508
Suicidal ideation	47.74	38.75	27	2187	8491	1736076
Atrial fibrillation	47.08	38.75	33	2181	15078	1729489
Unmasking of previously unidentified disease	46.56	38.75	9	2205	79	1744488
Low birth weight baby	46.44	38.75	14	2200	873	1743694
Depression	46.43	38.75	34	2180	16635	1727932
Delirium	46.34	38.75	24	2190	6338	1738229
Head injury	45.93	38.75	19	2195	3005	1741562
Inappropriate schedule of product administration	45.50	38.75	25	2189	7434	1737133
Loss of consciousness	45.22	38.75	32	2182	14843	1729724
Tremor	44.01	38.75	30	2184	13101	1731466
Drug ineffective for unapproved indication	43.81	38.75	16	2198	1813	1742754
Abnormal behaviour	43.55	38.75	23	2191	6319	1738248
Hippocampal sclerosis	43.54	38.75	7	2207	17	1744550
Amnesia	43.11	38.75	21	2193	4870	1739697
Psychotic disorder	42.45	38.75	21	2193	5035	1739532
Drug interaction	42.24	38.75	40	2174	27918	1716649
Exposure via breast milk	41.76	38.75	10	2204	256	1744311
Pneumonia aspiration	41.64	38.75	21	2193	5245	1739322
Anomaly of external ear congenital	41.51	38.75	8	2206	69	1744498
Coarctation of the aorta	41.48	38.75	9	2205	146	1744421
Condition aggravated	41.32	38.75	35	2179	21115	1723452
Postictal psychosis	41.31	38.75	7	2207	26	1744541
Mydriasis	40.93	38.75	14	2200	1310	1743257
Hyperammonaemia	39.68	38.75	13	2201	1065	1743502

Pharmacologic Action:

Source	Code	Description
ATC	N03AX18	NERVOUS SYSTEM ANTIEPILEPTICS ANTIEPILEPTICS Other antiepileptics
FDA EPC	N0000175753	Anti-epileptic Agent
FDA PE	N0000008486	Decreased Central Nervous System Disorganized Electrical Activity
MeSH PA	D000927	Anticonvulsants
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D026941	Sodium Channel Blockers
MeSH PA	D061567	Voltage-Gated Sodium Channel Blockers

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Partial Epilepsy Treatment Adjunct	indication
Atrial flutter	contraindication	5370000
Suicidal thoughts	contraindication	6471006
Complete atrioventricular block	contraindication	27885002
Orthostatic hypotension	contraindication	28651003
Sick sinus syndrome	contraindication	36083008	DOID:13884
Chronic heart failure	contraindication	48447003
Atrial fibrillation	contraindication	49436004	DOID:0060224
Acute nephropathy	contraindication	58574008
Second degree atrioventricular block	contraindication	195042002
Disease of liver	contraindication	235856003	DOID:409
Suicidal	contraindication	267073005
Disorder of coronary artery	contraindication	414024009
Myocardial ischemia	contraindication	414795007	DOID:3393
Severe Cardiac Disease	contraindication
First Degree Atrioventricular Heart Block	contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.83	acidic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
100MG	VIMPAT	UCB INC	N022253	Oct. 28, 2008	RX	TABLET	ORAL	RE38551	March 17, 2022	METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER
100MG	VIMPAT	UCB INC	N022253	Oct. 28, 2008	RX	TABLET	ORAL	RE38551	March 17, 2022	METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
150MG	VIMPAT	UCB INC	N022253	Oct. 28, 2008	RX	TABLET	ORAL	RE38551	March 17, 2022	METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER
150MG	VIMPAT	UCB INC	N022253	Oct. 28, 2008	RX	TABLET	ORAL	RE38551	March 17, 2022	METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
200MG	VIMPAT	UCB INC	N022253	Oct. 28, 2008	RX	TABLET	ORAL	RE38551	March 17, 2022	METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER
200MG	VIMPAT	UCB INC	N022253	Oct. 28, 2008	RX	TABLET	ORAL	RE38551	March 17, 2022	METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
50MG	VIMPAT	UCB INC	N022253	Oct. 28, 2008	RX	TABLET	ORAL	RE38551	March 17, 2022	METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER
50MG	VIMPAT	UCB INC	N022253	Oct. 28, 2008	RX	TABLET	ORAL	RE38551	March 17, 2022	METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
200MG/20ML (10MG/ML)	VIMPAT	UCB INC	N022254	Oct. 28, 2008	RX	SOLUTION	INTRAVENOUS	RE38551	March 17, 2022	METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE
200MG/20ML (10MG/ML)	VIMPAT	UCB INC	N022254	Oct. 28, 2008	RX	SOLUTION	INTRAVENOUS	RE38551	March 17, 2022	METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE
10MG/ML	VIMPAT	UCB INC	N022255	April 20, 2010	RX	SOLUTION	ORAL	RE38551	March 17, 2022	METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER
10MG/ML	VIMPAT	UCB INC	N022255	April 20, 2010	RX	SOLUTION	ORAL	RE38551	March 17, 2022	METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
100MG	VIMPAT	UCB INC	N022253	Oct. 28, 2008	RX	TABLET	ORAL	Nov. 3, 2020	NEW PATIENT POPULATION
150MG	VIMPAT	UCB INC	N022253	Oct. 28, 2008	RX	TABLET	ORAL	Nov. 3, 2020	NEW PATIENT POPULATION
200MG	VIMPAT	UCB INC	N022253	Oct. 28, 2008	RX	TABLET	ORAL	Nov. 3, 2020	NEW PATIENT POPULATION
50MG	VIMPAT	UCB INC	N022253	Oct. 28, 2008	RX	TABLET	ORAL	Nov. 3, 2020	NEW PATIENT POPULATION
200MG/20ML (10MG/ML)	VIMPAT	UCB INC	N022254	Oct. 28, 2008	RX	SOLUTION	INTRAVENOUS	Nov. 3, 2020	INCORPORATION OF THE LABELING REVISIONS PROVIDED FOR IN NDA 022253/S-039 AND NDA 022255/S-022 INTO THE LACOSAMIDE INJECTION LABELING
10MG/ML	VIMPAT	UCB INC	N022255	April 20, 2010	RX	SOLUTION	ORAL	Nov. 3, 2020	NEW PATIENT POPULATION

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium channel protein type 9 subunit alpha	Ion channel	Q15858	SCN9A_HUMAN	BLOCKER	IC50	6.74	CHEMBL	CHEMBL
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN		Ki	6.48	CHEMBL
Carbonic anhydrase 12	Enzyme	O43570	CAH12_HUMAN		Ki	5.43	CHEMBL
Carbonic anhydrase 4	Enzyme	P22748	CAH4_HUMAN		Ki	6.28	CHEMBL
Carbonic anhydrase 13	Enzyme	Q8N1Q1	CAH13_HUMAN		Ki	5.92	CHEMBL
Carbonic anhydrase 3	Enzyme	P07451	CAH3_HUMAN		Ki	6.43	CHEMBL
Carbonic anhydrase 5A, mitochondrial	Enzyme	P35218	CAH5A_HUMAN		Ki	5.34	CHEMBL
Carbonic anhydrase 14	Enzyme	Q9ULX7	CAH14_HUMAN		Ki	6.33	CHEMBL
Carbonic anhydrase 7	Enzyme	P43166	CAH7_HUMAN		Ki	5.35	CHEMBL
Carbonic anhydrase 9	Enzyme	Q16790	CAH9_HUMAN		Ki	6.45	CHEMBL
Carbonic anhydrase 1	Enzyme	P00915	CAH1_HUMAN		Ki	6.44	CHEMBL
Carbonic anhydrase 5B, mitochondrial	Enzyme	Q9Y2D0	CAH5B_HUMAN		Ki	6.47	CHEMBL
Carbonic anhydrase 6	Enzyme	P23280	CAH6_HUMAN		Ki	6.39	CHEMBL
Dihydropyrimidinase-related protein 2	Unclassified	Q16555	DPYL2_HUMAN				WOMBAT-PK
Sodium channel protein type X alpha subunit	Unclassified		SCNAA_RAT		IC50	4.80	CHEMBL
Sodium channel protein type 3 subunit alpha	Ion channel		SCN3A_RAT		IC50	6.38	CHEMBL
Carbonic anhydrase 15	Enzyme		CAH15_MOUSE		Ki	6.34	CHEMBL
Sodium channel protein type 2 subunit alpha	Ion channel		SCN2A_RAT	BLOCKER	IC50	4.52	IUPHAR

External reference:

ID	Source
D000078334	MESH_DESCRIPTOR_UI
4028103	VUID
N0000179735	NUI
C0893761	UMLSCUI
D07299	KEGG_DRUG
563KS2PQY5	UNII
8094	INN_ID
441532003	SNOMEDCT_US
623400	RXNORM
25914	MMSL
d07349	MMSL
4028103	VANDF
441647003	SNOMEDCT_US
012839	NDDF
CHEMBL58323	ChEMBL_ID
C476828	MESH_SUPPLEMENTAL_RECORD_UI
DB06218	DRUGBANK_ID
CHEBI:135939	CHEBI
219078	PUBCHEM_CID
7472	IUPHAR_LIGAND_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Vimpat	HUMAN PRESCRIPTION DRUG LABEL	1	0131-1810	INJECTION	10 mg	INTRAVENOUS	NDA	19 sections
Vimpat	HUMAN PRESCRIPTION DRUG LABEL	2	0131-2470	KIT	50 mg	None	NDA	19 sections
Vimpat	HUMAN PRESCRIPTION DRUG LABEL	2	0131-2470	KIT	100 mg	None	NDA	19 sections
Vimpat	HUMAN PRESCRIPTION DRUG LABEL	1	0131-2477	TABLET, FILM COATED	50 mg	ORAL	NDA	19 sections
Vimpat	HUMAN PRESCRIPTION DRUG LABEL	1	0131-2478	TABLET, FILM COATED	100 mg	ORAL	NDA	19 sections
Vimpat	HUMAN PRESCRIPTION DRUG LABEL	1	0131-2479	TABLET, FILM COATED	150 mg	ORAL	NDA	19 sections
Vimpat	HUMAN PRESCRIPTION DRUG LABEL	1	0131-2480	TABLET, FILM COATED	200 mg	ORAL	NDA	19 sections
Vimpat	HUMAN PRESCRIPTION DRUG LABEL	1	0131-5410	SOLUTION	10 mg	ORAL	NDA	19 sections
Vimpat	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6077	TABLET, FILM COATED	50 mg	ORAL	NDA	18 sections
Lacosamide	HUMAN PRESCRIPTION DRUG LABEL	1	63850-0053	TABLET, FILM COATED	50 mg	ORAL	ANDA	18 sections
Lacosamide	HUMAN PRESCRIPTION DRUG LABEL	1	63850-0054	TABLET, FILM COATED	100 mg	ORAL	ANDA	18 sections
Lacosamide	HUMAN PRESCRIPTION DRUG LABEL	1	63850-0055	TABLET, FILM COATED	150 mg	ORAL	ANDA	18 sections
Lacosamide	HUMAN PRESCRIPTION DRUG LABEL	1	63850-0056	TABLET, FILM COATED	200 mg	ORAL	ANDA	18 sections
Lacosamide	HUMAN PRESCRIPTION DRUG LABEL	1	65162-912	SOLUTION	10 mg	ORAL	ANDA	19 sections
Vimpat	HUMAN PRESCRIPTION DRUG LABEL	1	70166-617	SOLUTION	10 mg	ORAL	NDA	19 sections
Vimpat	HUMAN PRESCRIPTION DRUG LABEL	1	70518-0257	TABLET, FILM COATED	100 mg	ORAL	NDA	19 sections